TABLE 1.
Mean values (SD) for PD on demographic and clinical assessment carried out by the neurologist prior to the study.
| Neurological assessment | Means (SD) | On-phase | Off-phase |
| Gender (male/female) | 14/1 | ||
| PD-CRS | 89.2 (12.97) | ||
| Disease (years): | |||
| Since the first symptoms appeared | 6.87 (4.61) | ||
| Since the diagnosis was made | 5.56 (4.51) | ||
| L-dopa (months of treatment) | 44.4 (47.87) | ||
| L-dopa (mg) | 439.28 (268.13) | ||
| LED (mg) | 729.53 (298.23) | ||
| UPDRS total score | 25.6 (13.20) | 24.6 (11.76) | |
| Part I | 0.80 (0.94) | 1.86 (4.06) | |
| Part II | 6.66 (5.05) | 5.80 (4.41) | |
| Part III | 17.13 (10.20) | 16.8 (8.91) | |
| Part IV | 1.4 (1.33) | 1.6 (1.26) | |
| Hoehn and Yahr scale | 1.77 (0.37) | 1.8 (0.36) | |
PD-CRS, Parkinson’s Disease-Cognitive Rating Scale; LED, total daily Levodopa equivalent dose; UPDRS, Unified Parkinson Disease Rating Scale (Fahn et al., 1987); H&Y, Hoehn and Yahr scale. For each patient, the levodopa equivalent dose (LED) was calculated following the procedures of Tomlinson et al. (2010).